Opinion
Video
Author(s):
Urologists offer their perspectives on toxicity seen in patients with prostate cancer who are undergoing radiation treatment.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
PEACE-3 data for radium-223/enzalutamide published in Annals of Oncology
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025
ORIC-944 shows promise in combination with AR inhibitors in mCRPC
Dr. Murphy on increasing diversity in cancer clinical trials
Combination therapy linked to longer OS vs ADT in veterans with mHSPC
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
Phase 2 trial launches of combination immunotherapy for mCRPC
Study findings highlight gender gaps in oncology authorship and citation